

Special Issue

Diagnosis of Hematologic Malignancies: 2nd Edition

Message from the Guest Editors

In recent years, we have experienced a change in the paradigm of the diagnosis of hematological malignancies, moving from phenotyping to genotyping, and giving increasing importance to multidisciplinary diagnoses. The World Health Organization's (WHO) classification of tumors of hematopoietic and lymphoid tissues has provided a global reference for the diagnosis of hematological neoplasms since its third edition in 2001. This classification is based on integrating morphologic (cytology and histology), immunophenotypic, molecular, and cytogenetic data. Recently, in addition to the 2022 edition of the WHO classification, the International Consensus Classification (ICC) system for hematological neoplasms has been published. While many definitions proposed by the ICC and WHO 2022 are concordant, some differ in a number of key aspects and could impact the design of clinical trials, drug development, and regulatory approval, in addition to, as a consequence, patient care. With this, the current Special Issue aims to highlight novel diagnostic and prognostic tools that could improve the management and treatment of hematological neoplasms—we look forward to your contributions.

Guest Editors

Dr. Leonor Arenillas

1. Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain
2. Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain

Dr. Xavier Calvo

1. Hematological Cytology Laboratory, Pathology Department, Hospital del Mar, 08003 Barcelona, Spain
2. Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar Research Institute (HMRI), 08003 Barcelona, Spain

Deadline for manuscript submissions

10 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/234367

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)